A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib by Mary Clark, MD, Paul Imbriano, DO, Michael Harwood, MD, Klaus Busam, MD, Leslie Robinson-Bostom, MD

Get full text